financetom
Business
financetom
/
Business
/
DexCom Reports Higher Preliminary Q4, Full-Year 2024 Revenue; Sets 2025 Revenue Guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
DexCom Reports Higher Preliminary Q4, Full-Year 2024 Revenue; Sets 2025 Revenue Guidance
Jan 13, 2025 5:57 AM

08:37 AM EST, 01/13/2025 (MT Newswires) -- DexCom ( DXCM ) reported preliminary Q4 revenue Monday of $1.11 billion, up 8% from a year earlier.

Analysts polled by FactSet expected 1.10 billion.

The company also said it expects Q4 gross margin to be "adversely impacted" by a non-cash charge for inventory that was damaged in transit as well as lower production yield.

The company also reported preliminary full-year 2024 revenue of $4.03 billion, up 11% from a year earlier.

Analysts surveyed by FactSet expected $4.02 billion.

DexCom ( DXCM ) also said it expects full-year 2025 revenue of $4.60 billion. Analysts polled by FactSet are looking for $4.61 billion.

Shares of DexCom ( DXCM ) were up 5.8% in recent premarket activity.

Price: 82.24, Change: +4.48, Percent Change: +5.76

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Kidoz's Third-Quarter Loss Narrows as Revenue Hits Record
Kidoz's Third-Quarter Loss Narrows as Revenue Hits Record
Nov 20, 2025
04:27 PM EST, 11/20/2025 (MT Newswires) -- Kidoz (KDOZ.V) on Thursday reported a narrower third-quarter loss as strong advertising demand drove a 60% jump in revenue. The company posted a loss of US$177,711, an improvement from a loss of US$406,284 a year earlier. Revenue rose to a record US$3.67 million from US$2.29 million a year earlier, reflecting continued growth across...
Revolution Medicines Insider Sold Shares Worth $1,407,586, According to a Recent SEC Filing
Revolution Medicines Insider Sold Shares Worth $1,407,586, According to a Recent SEC Filing
Nov 20, 2025
04:29 PM EST, 11/20/2025 (MT Newswires) -- Mark A Goldsmith, Director, President and Chief Executive Officer, on November 18, 2025, sold 20,000 shares in Revolution Medicines ( RVMD ) for $1,407,586. Following the Form 4 filing with the SEC, Goldsmith has control over a total of 958,761 common shares of the company, with 247,863 shares held directly and 710,898 controlled...
Matthews International Fiscal Q4 Adjusted Earnings, Revenue Fall
Matthews International Fiscal Q4 Adjusted Earnings, Revenue Fall
Nov 20, 2025
04:27 PM EST, 11/20/2025 (MT Newswires) -- Matthews International ( MATW ) reported fiscal Q4 adjusted earnings late Thursday of $0.50 per share, down from $0.55 a year earlier. Two analysts polled by FactSet expected $0.20. Revenue for the three months ended Sept. 30 was $318.8 million, down from $446.7 million a year earlier. Two analysts surveyed by FactSet expected...
Revolution Medicines Insider Sold Shares Worth $939,008, According to a Recent SEC Filing
Revolution Medicines Insider Sold Shares Worth $939,008, According to a Recent SEC Filing
Nov 20, 2025
04:29 PM EST, 11/20/2025 (MT Newswires) -- Jeff Cislini, General Counsel, on November 18, 2025, sold 13,388 shares in Revolution Medicines ( RVMD ) for $939,008. Following the Form 4 filing with the SEC, Cislini has control over a total of 50,425 common shares of the company, with 50,425 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1628171/000161071725000383/xslF345X05/form4.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved